Trial Profile
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-Cell Lymphoblastic Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Methotrexate (Primary) ; Nelarabine (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Folinic acid; Folinic acid; Mercaptopurine; Methotrexate; Pegaspargase; Pegaspargase; Prednisone; Prednisone; Tioguanine; Vincristine
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results from AALL0434 and AALL1231 , presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Aug 2023 Results published in the Blood
- 07 Jun 2022 Results of an analysis assessing impact of dose modification based on various factors using data from two clinical studies: NCT00075725 and NCT00408005 presented at the 58th Annual Meeting of the American Society of Clinical Oncology